These 2 Quantum ETFs Could Climb More Than 29%, Analysts Say
TipRanks (Mon, 6-Jul 12:20 PM ET)
TipRanks (Wed, 1-Jul 1:30 PM ET)
Globe Newswire (Fri, 26-Jun 8:30 AM ET)
Quantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS Therapy
Globe Newswire (Thu, 25-Jun 8:30 AM ET)
The Quest to Repair What Multiple Sclerosis Takes Away
Globe Newswire (Wed, 24-Jun 8:30 AM ET)
Globe Newswire (Tue, 23-Jun 8:30 AM ET)
Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
Globe Newswire (Mon, 22-Jun 8:30 AM ET)
Globe Newswire (Tue, 2-Jun 8:00 AM ET)
Globe Newswire (Tue, 2-Jun 7:40 AM ET)
Quantum BioPharma Provides Corporate Update
Globe Newswire (Mon, 1-Jun 7:30 PM ET)
Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.
Quantum Biopharma Ltd. - Class B Subordinate Voting Shares trades on the NASDAQ stock market under the symbol QNTM.
As of July 6, 2026, QNTM stock price climbed to $3.60 with 49,310 million shares trading.
QNTM has a beta of 1.78, meaning it tends to be more sensitive to market movements. QNTM has a correlation of 0.02 to the broad based SPY ETF.
QNTM has a market cap of $23.04 million. This is considered a Sub-Micro Cap stock.
Last quarter Quantum Biopharma Ltd. - Class B Subordinate Voting Shares reported $0 in Revenue and -$3.06 earnings per share. This fell short of revenue expectation by $-1 million and missed earnings estimates by -$2.50.
QNTM has underperformed the market in the last year with a price return of -81.2% while the SPY ETF gained +22.2%. QNTM has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -9.5% and -5.3%, respectively, while the SPY returned +14.8% and +0.5%, respectively.
QNTM support price is $3.26 and resistance is $3.76 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that QNTM shares will trade within this expected range on the day.
